Anti-Cd30 Bispecific Antibody-Armed Anti-Cd3-Activated Autologous T-Cells
CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma
Medical College of WisconsinCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Brentuximab Vedotin John Reneau | Phase 3 | BB |
Bexarotene Millennium Pharmaceuticals, Inc. | Phase 3 | BB |
METHOTREXATE Millennium Pharmaceuticals, Inc. | Phase 3 | BB |
cc-5013 John Reneau | Phase 2 | B |
Pralatrexate Acrotech Biopharma Inc. | Phase 1 | CC |
View all 9 →
Same molecule, other indications
Anti-Cd30 Bispecific Antibody-Armed Anti-Cd3-Activated Autologous T-Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →